Artigos com autorizações de acesso público - Nancy K SweitzerSaiba mais
Não disponíveis em nenhum local: 3
Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee
JC Fang, GA Ewald, LA Allen, J Butler, CAW Canary, M Colvin-Adams, ...
Journal of cardiac failure 21 (6), 519-534, 2015
Autorizações: US National Institutes of Health
Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial
AS Desai, J Liu, MA Pfeffer, B Claggett, J Fleg, EF Lewis, S McKinlay, ...
Journal of cardiac failure 24 (5), 313-320, 2018
Autorizações: US National Institutes of Health
Heart failure in non-Caucasians, women, and older adults: a white paper on special populations from the Heart Failure Society of America Guideline Committee
M Colvin, NK Sweitzer, NM Albert, R Krishnamani, MW Rich, WG Stough, ...
Journal of cardiac failure 21 (8), 674-693, 2015
Autorizações: US National Institutes of Health
Disponíveis em algum local: 109
Spironolactone for heart failure with preserved ejection fraction
B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ...
New England Journal of Medicine 370 (15), 1383-1392, 2014
Autorizações: US National Institutes of Health
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
MA Pfeffer, B Claggett, SF Assmann, R Boineau, IS Anand, N Clausell, ...
Circulation 131 (1), 34-42, 2015
Autorizações: US National Institutes of Health
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
SD Solomon, B Claggett, EF Lewis, A Desai, I Anand, NK Sweitzer, ...
European heart journal 37 (5), 455-462, 2016
Autorizações: US National Institutes of Health
High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure
B Ky, B French, K McCloskey, JE Rame, E McIntosh, P Shahi, DL Dries, ...
Circulation: heart failure 4 (2), 180-187, 2011
Autorizações: US National Institutes of Health
Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone
AM Shah, B Claggett, NK Sweitzer, SJ Shah, IS Anand, L Liu, B Pitt, ...
Circulation 132 (5), 402-414, 2015
Autorizações: US National Institutes of Health
Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF
JJV McMurray, AM Jackson, CSP Lam, MM Redfield, IS Anand, J Ge, ...
Circulation 141 (5), 338-351, 2020
Autorizações: British Heart Foundation
Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes
A Basuray, B French, B Ky, E Vorovich, C Olt, NK Sweitzer, TP Cappola, ...
Circulation 129 (23), 2380-2387, 2014
Autorizações: US National Institutes of Health
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac …
AM Shah, SJ Shah, IS Anand, NK Sweitzer, E O’Meara, JF Heitner, ...
Circulation: Heart Failure 7 (1), 104-115, 2014
Autorizações: US National Institutes of Health
Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction
ABS Santos, GQ Roca, B Claggett, NK Sweitzer, SJ Shah, IS Anand, ...
Circulation: Heart Failure 9 (4), e002763, 2016
Autorizações: US National Institutes of Health, American Heart Association
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac …
AM Shah, B Claggett, NK Sweitzer, SJ Shah, IS Anand, E O’Meara, ...
Circulation: Heart Failure 7 (5), 740-751, 2014
Autorizações: US National Institutes of Health
Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure
B Ky, B French, A May Khan, T Plappert, A Wang, JA Chirinos, JC Fang, ...
Journal of the American College of Cardiology 62 (13), 1165-1172, 2013
Autorizações: US National Institutes of Health
Multiple biomarkers for risk prediction in chronic heart failure
B Ky, B French, WC Levy, NK Sweitzer, JC Fang, AHB Wu, LR Goldberg, ...
Circulation: Heart Failure 5 (2), 183-190, 2012
Autorizações: US National Institutes of Health
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
JB Cohen, TC Hanff, P William, N Sweitzer, NR Rosado-Santander, ...
The lancet respiratory medicine 9 (3), 275-284, 2021
Autorizações: US National Institutes of Health, American Heart Association
Thyroid dysfunction in heart failure and cardiovascular outcomes
L Kannan, PA Shaw, MP Morley, J Brandimarto, JC Fang, NK Sweitzer, ...
Circulation: Heart Failure 11 (12), e005266, 2018
Autorizações: US National Institutes of Health
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
SJ Shah, JF Heitner, NK Sweitzer, IS Anand, HY Kim, B Harty, R Boineau, ...
Circulation: Heart Failure 6 (2), 184-192, 2013
Autorizações: US National Institutes of Health
Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (≥ 55%) versus those with mildly reduced (40% to 55%) and …
NK Sweitzer, M Lopatin, CW Yancy, RM Mills, LW Stevenson
The American journal of cardiology 101 (8), 1151-1156, 2008
Autorizações: US National Institutes of Health
Sex differences in outcomes and responses to spironolactone in heart failure with preserved ejection fraction: a secondary analysis of TOPCAT trial
M Merrill, NK Sweitzer, JA Lindenfeld, DP Kao
JACC: Heart Failure 7 (3), 228-238, 2019
Autorizações: US National Institutes of Health, American Heart Association
As informações de publicação e financiamento são determinadas automaticamente por um programa informático.